Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide

Bone Marrow Transplantation

Volumn 46, Issue 3, 2011, Pages 350-355

  Micallef, I N M ^a   Ho, A D ^b   Klein, L M ^c   Marulkar, S ^d   Gandhi, P J ^d   McSweeney, P A ^e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c ADVOCATE LUTHERAN GENERAL HOSPITAL   (United States)

^d GENZYME CORPORATION   (United States)

^e ROCKY MOUNTAIN CANCER CENTERS   (United States)

Author keywords

auto SCT; lenalidomide; mobilization; multiple myeloma; plerixafor; G CSF

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLERIXAFOR;

ADULT; ARTICLE; CD34 SELECTION; CELL COUNT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; BLOOD COMPONENT REMOVAL; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; THALIDOMIDE;

EID: 79952536052     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.118     Document Type: Article

References (31)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome. N Engl J Med 1996; 335: 91-97. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883. (Pubitemid 36532313)
3. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436. (Pubitemid 46630462)
4. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Mohty M et al. VELCADE/dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): updated results of the IFM 2005/01 trial. Blood (ASH Annual Meeting Abstracts) 2007; 110 abstract 450.
5. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123-2132. (Pubitemid 350146107)
6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133-2142. (Pubitemid 350146108)
7. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050-4053. (Pubitemid 41775908)
8. Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Geyer S, Kabat B et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexa-methasone in newly diagnosed myeloma. Mayo Clin Proc 2007; 82: 1179-1184. (Pubitemid 47502875)
9. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF et al. Superiority of lenalidomide (len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood (ASH Annual Meeting Abstracts) 2007; 110 abstract 77.
10. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams M et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood (ASH Annual Meeting Abstracts) 2007; 110 abstract 74.
11. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904-1912.
12. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042. (Pubitemid 47299979)
13. Kumar S, Lacy M, Dispenzieri A, Hayman S, Buadi F, Dingli D et al. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2008; 112 abstract 3467.
14. Mark T, Stern J, Furst JR, Jayabalan D, Zafar F, LaRow A et al. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 795-798. (Pubitemid 351773154)
15. Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008; 22: 1280-1281; author reply 1281-1282. (Pubitemid 351833803)
16. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N et al. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282-1284. (Pubitemid 351833805)
17. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-723.
18. Genzyme Corporation. Mozobil [package insert] 2008. Cam-bridge, MA: Genzyme Corporation.
19. Flomenberg N, Devine SM, DiPersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobiliza-tion is superior to G-CSF alone. Blood 2005; 106: 1867-1874. (Pubitemid 41208607)
20. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for auto-logous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
21. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338.
22. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909-917.
23. Tricot G, Cottler-Fox M, Calandra G. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assess-ment of tumor cell mobilization. Bone Marrow Transplant 2010; 45: 63-68.
24. Alegre A, Tomas JF, Mart?nez-Chamorro C, Gil-Fernandez JJ, Fernandez-Villalta MJ, Arranz R et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211-217. (Pubitemid 27361913)
25. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547-1553. (Pubitemid 28175779)
26. Koç ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macro-phage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-1830. (Pubitemid 30261919)
27. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection follow-ing initial therapy with thalidomide, lenalidomide or bortezo-mib-containing regimens. Blood 2009; 114: 1729-1735.
28. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619-625.
29. Dingli D, Nowakowski GS, Dispenzieri A, Lacy MQ, Hayman S, Litzow MR et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplanta-tion for multiple myeloma. Clin Lymphoma Myeloma 2006; 6: 384-388.
30. Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho AD et al. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multi-ple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant 2010; 45: 269-275.
31. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249-256.